 |
 |
On 18 Feb 00 at 17:21, janet marie paterson wrote: > >Subject: Panel Recommendations Regarding Tolcapone > >Date: Fri, 18 Feb 2000 11:09:19 -0600 > > > >Tolcapone and hepatotoxic effects > >CW Olanow, and the Tasmar Advisory Panel > >Arch Neurol 2000;57:263-267 > >http://archneur.ama-assn.org/issues/v57n2/full/nob8443.html > > > >The risk of developing irreversible liver injury from tolcapone is > >negligible with proper monitoring, according to this editorial. SNIP Hi Janet, This is interesting and I was prompted to look at Roche US site. Revamped and quite extensive... (and addresses for Ivan's queries) Roche Tasmar Welcome to the official Tasmar r website. http://www.tasmar.com/index.html link away to lotsa pages on their site.... Health Canada's '98 "Ban" Liver complications reported with anti-Parkinson's drug TASMAR http://www.hc-sc.gc.ca/english/archives/warnings/98_88e.htm Tolcapone (Tasmar) & Hepatoxic Effects http://archneur.ama-assn.org/issues/v57n2/full/nob8443.html Janet, I thank you very much for this news item..... murray [log in to unmask]